FY2010 Extramural NHLBI projects (including all mechanisms) by RCDC topics that relate to specific disease categories
| RCDC topic . | Nonclinical projects . | Clinical projects . | ||||
|---|---|---|---|---|---|---|
| No. . | Total funding (% extramural funding) . | Median cost per project (25th, 75th percentiles) . | No. . | Total funding (% extramural funding) . | Median cost per project (25th and 75th percentiles) . | |
| Cardiovascular | 1913 | 865 499 (35%) | 374 (270, 414) | 1005 | 539 545 (22%) | 379 (142, 658) |
| Atherosclerosis | 393 | 243 991 (10%) | 375 (303, 414) | 271 | 160 713 (7%) | 401 (198, 722) |
| CAD | 440 | 221 791 (9%) | 380 (323, 420) | 267 | 156 696 (6%) | 422 (200, 721) |
| Heart disease | 1258 | 595 073 (24%) | 375 (286, 417) | 727 | 410 409 (17%) | 386 (147, 685) |
| Hypertension | 231 | 105 746 (4%) | 370 (312, 401) | 111 | 50 652 (2%) | 371 (151, 594) |
| Lung | 697 | 325 329 (13%) | 376 (293, 410) | 605 | 283 649 (12%) | 375 (137, 610) |
| COPD | 55 | 58 142 (2%) | 410 (346, 1730) | 84 | 44 767 (2%) | 372 (142, 703) |
| Asthma | 94 | 40 732 (2%) | 373 (249, 400) | 144 | 79 092 (3%) | 407 (160, 750) |
| ARDS | 110 | 61 255 (3%) | 384 (335, 410) | 82 | 29 665 (1%) | 326 (135, 415) |
| Cystic fibrosis | 42 | 21 253 (1%) | 371 (326, 475) | 37 | 17 928 (1%) | 385 (173, 648) |
| Sleep | 55 | 16 969 (1%) | 367 (230, 393) | 97 | 51 527 (2%) | 405 (189, 607) |
| Hematology | 406 | 165 228 (7%) | 370 (191, 410) | 295 | 139 989 (6%) | 375 (140, 464) |
| Sickle cell | 21 | 9325 (< 1%) | 338 (139, 458) | 60 | 28 774 (1%) | 303 (125, 451) |
| Cooley anemia | 9 | 4949 (< 1%) | 394 (373, 429) | 9 | 8112 (< 1%) | 411 (390, 1327) |
| RCDC topic . | Nonclinical projects . | Clinical projects . | ||||
|---|---|---|---|---|---|---|
| No. . | Total funding (% extramural funding) . | Median cost per project (25th, 75th percentiles) . | No. . | Total funding (% extramural funding) . | Median cost per project (25th and 75th percentiles) . | |
| Cardiovascular | 1913 | 865 499 (35%) | 374 (270, 414) | 1005 | 539 545 (22%) | 379 (142, 658) |
| Atherosclerosis | 393 | 243 991 (10%) | 375 (303, 414) | 271 | 160 713 (7%) | 401 (198, 722) |
| CAD | 440 | 221 791 (9%) | 380 (323, 420) | 267 | 156 696 (6%) | 422 (200, 721) |
| Heart disease | 1258 | 595 073 (24%) | 375 (286, 417) | 727 | 410 409 (17%) | 386 (147, 685) |
| Hypertension | 231 | 105 746 (4%) | 370 (312, 401) | 111 | 50 652 (2%) | 371 (151, 594) |
| Lung | 697 | 325 329 (13%) | 376 (293, 410) | 605 | 283 649 (12%) | 375 (137, 610) |
| COPD | 55 | 58 142 (2%) | 410 (346, 1730) | 84 | 44 767 (2%) | 372 (142, 703) |
| Asthma | 94 | 40 732 (2%) | 373 (249, 400) | 144 | 79 092 (3%) | 407 (160, 750) |
| ARDS | 110 | 61 255 (3%) | 384 (335, 410) | 82 | 29 665 (1%) | 326 (135, 415) |
| Cystic fibrosis | 42 | 21 253 (1%) | 371 (326, 475) | 37 | 17 928 (1%) | 385 (173, 648) |
| Sleep | 55 | 16 969 (1%) | 367 (230, 393) | 97 | 51 527 (2%) | 405 (189, 607) |
| Hematology | 406 | 165 228 (7%) | 370 (191, 410) | 295 | 139 989 (6%) | 375 (140, 464) |
| Sickle cell | 21 | 9325 (< 1%) | 338 (139, 458) | 60 | 28 774 (1%) | 303 (125, 451) |
| Cooley anemia | 9 | 4949 (< 1%) | 394 (373, 429) | 9 | 8112 (< 1%) | 411 (390, 1327) |
All costs are in units of $1000. All data were obtained from the NIH Research Portfolio Online Reporting Tools (RePORT). Estimates of funding for various RCDCs are at http://report.nih.gov/categorical_spending.aspx. RCDC topics are not necessarily exclusive of one another (hence, total percentages exceed 100). Clinical projects are those categorized in RCDC as “Clinical Research” or “Clinical Trials.” Total NHLBI extramural funding in FY10 was $2 441 772 050. Numbers of projects, total funding in each RCDC area, and median (25th, 75th percentiles) costs per project were calculated using the SAS Version 9.2 “Proc Tabulate” procedure.
CAD indicates coronary artery disease; COPD, chronic obstructive pulmonary disease; and ARDS, acute respiratory distress syndrome.